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Introduction
Leishmaniases are zoonoses that manifest in the 
cutaneous, mucocutaneous and visceral forms.1 Among 
all parasitic infections, leishmaniasis, which is related 
to 20 000–30 000 deaths annually, ranking second in 
mortality after malaria.1,2 Leishmaniasis is a vector-
borne, infectious disease endemic to 98 countries. 
Transmission occurs through the bite of a naturally 
infected Phlebotomus in the Old World or Lutzomyia in 
the New World.3 Cutaneous leishmaniasis (CL) is the 
most common type, with an estimated 0.6–1.0 million 
new cases occurring each year, corresponding to 75% 
of all diagnosed cases of leishmaniasis.1 The cutaneous 
disease is mainly caused by subgenus Leishmania (e.g., 
L. major, L. tropica, L. mexicana, L. amazonensis) in the 
Middle East, Asia, and Africa, while the subgenus Viannia 
(L. naiffi, L. braziliensis, L. guyanensis, L. panamensis) is 
responsible for most cases occurring in the Americas.4 
More than 90% of CL cases occur in Afghanistan, Algeria, 
Brazil, Colombia, Iran and Syria.1 In Brazil, the Ministry of 
Health, through the National Health Information System, 
has estimated that the incidence rate of CL in the country 
is 11.1 cases/100 000 inhabitants.5
Visceral leishmaniasis (VL; also known as the kala–azar 
disease) is caused by L. (L.) infantum, L. chagasi, or L. 
donovani complexes.6 Although less frequent, VL affects 
50 000 to 90 000 individuals annually and is the most 
severe form of the disease. It is characterized by fever, 
pancytopenia, thrombocytopenia, hepatosplenomegaly, 
pain, and abdominal distention, wasting and 
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• Splenic hamster cells
Abstract
Purpose: Here, we aim to evaluate the antileishmanial activity of compounds with a 
benzoxazinoid (BX) skeleton, previously synthesized by our group, against Leishmania (Viannia) 
braziliensis and Leishmania (Leishmania) infantum promastigotes. 
Methods: Anti-promastigote activity, as well as cytotoxicity, were determined using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assays. The 
selectivity index (SI) for each compound was calculated using a ratio of the cytotoxicity of 
compounds and the geometric mean (GM) of antileishmanial concentrations to each species 
tested. The comparisons between groups were carried out using a t test or analysis of variance 
(one-way ANOVA). A P value of less than 0.05 was considered significant. 
Results: All the compounds tested were active, with IC50 falling between 92 ± 6.19 µg/mL 
and 238±6.57 µg/mL for L. braziliensis, and 89 ± 6.43 µg/mL and 188 ± 3.58 µg/mL against L. 
infantum. Bex2, Bex3, Pyr1, Pyr2, and Pyr4 were compounds that showed activity similar to 
the drug Glucantime®, exhibited low cytotoxicity against splenic hamster cells (CC50 raging 
between >400 and 105.7±2.26 µg/mL) and had favorable selectivity indices (SI 1.12 to 3.96). 
Conclusion: The analogs in question are promising prototypes for the pharmaceutical 
development of novel, safer and more effective leishmanicidal agents.
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malnutrition.1,6 Currently, particular attention has been 
given to this type of leishmaniasis due to significant 
changes the transmission cycle of the disease, which has 
become increasingly urbanized and anthropophilic.7 
In 2015, Brazil, Ethiopia, India, Kenya, Somalia, South 
Sudan, and Sudan accounted for more than 90% of cases 
of VL,1 and between 2000–2010, an average of 3484 new 
cases each year were reported in Brazil.7
The therapeutic arsenal used to leishmaniases is basically 
composed by pentavalent antimony, paromomycin, 
pentamidine, miltefosine, and amphotericin B.8 However, 
these drugs have several limitations which include 
severe side effects (e.g., cardiac arrhythmias, myalgia, 
and pancreatitis associated to pentavalent antimonial), 
high toxicity, and require prolonged use. In addition 
patients in need of treatment exhibit a low adherence to 
treatment plans and there is an insufficient availability 
of drugs generally in endemic regions.9 Additionally, 
Leishmania strains with moderate and complete resistance 
to pentavalent antimonials and amphotericin B have 
already been identified in several parts of the world.10 
Problems with available therapies are even more pressing 
the pharmaceutical industry has neglected to investment 
in the research and development of new compounds 
with antileishmanial activity; a class of drugs that has 
represented less of 1% of drugs researched in the last year 
by the most prominent companies.11 Thus, the search for 
new pharmaceutical compounds is urgently needed to 
control leishmaniasis.
Currently, the World Health Organization (WHO) 
recommended the use of some herbal medicines as 
antileishmanial agents and several studies have determined 
that the phytoconstituents of these medicinal plants should 
be considered prototypes for new leishmanicidal drugs.1,9 
Thus, the benzoxazinoids (Bexs), which are allelochemical 
alkaloids widely distributed among monocotyledons of 
the Gramineae family, stand out as a potential targets 
in the search for new antileishmanial agents.12 Bexs are 
characterized by the presence of a 2-hydroxy-2H-1,4-
benzoxazin-3(4H)–one skeleton and are known to show 
anti-inflammatory, antinociceptive, reproductive and 
immune stimulatory, antitumor and appetite suppressor 
activities.12,13 Moreover, recent work has uncovered a 
critical antimicrobial activity for the compounds, covering 
bacteria, yeast, molds, and retroviruses of great medical 
importance.14–17
Our group has previously developed and synthesized a 
series of new Bex analogs that have shown antimicrobial 
activity against microorganisms of high medical 
relevance such as Enterococcus faecalis, Staphylococcus 
aureus, Acinetobacter baumannii, Candida albicans, C. 
tropicalis and C. glabrata.18 Here, we aimed to evaluate 
potential antileishmanial effects of these compounds 
against promastigotes of Leishmania (V.) braziliensis and 
Leishmania (L.) infantum and also aim determine the 
cytotoxicity of these analogs against hamster spleen cells.
Materials and Methods
Chemistry
The Bexs analogs employed in this study were provided 
by the Laboratory of Natural product chemistry, Federal 
University of Sao Joao Del-rei, Divinópolis, MG, Brazil. 
These compounds were synthesized according to the 
methodology described by Lima et al,18 and chemical 
structures of the compounds are shown in Figure 1.
Parasite culture
Promastigotes of Leishmania (V.) braziliensis (MHOM/
BR/75/M2903) and Leishmania (L.) infantum (MHOM/
BR/74/PP75) were grown in a biphasic medium. The 
solid phase was composed of Nicolle–Novy–MacNeals 
(NNN) medium with 15% defibrillated rabbit blood. 
Already in the liquid phase, we employed Roswell Park 
Memorial Institute (RPMI)-1640 (Sigma-Aldrich, St. 
Louis, USA) or Liver Infusion Tryptose (LIT) medium 
with 15% fetal bovine serum (Gibco – Thermo Fisher 
Scientific, Waltham USA), both supplemented with 1% 
of penicillin-streptomycin antibiotic solutions (10.000 U/
mL of penicillin and 10.000 μg/mL of streptomycin; Gibco 
– Thermo Fisher Scientific, Waltham, USA). Cultures 
were maintained in an incubator at 25°C until parasites 
reached logarithmic phase (4 days). Next, the cultures 
were centrifuged and the pellet was suspended in RPMI-
1640 or LIT for counting promastigotes using a Neubauer 
hemocytometer under an optical microscope (Axiostar 
Plus Carl Zeiss, Jena, Germany) at 400x magnification. 
Subsequently, parasites were diluted in RPMI-1640 or LIT 
medium at a final concentration of 1 x 106 parasites/mL 
for use in antileishmanial assays.
Anti-promastigote activity
The 50% inhibitory concentration (IC50) against L. 
(V.) braziliensis and L. (L.) infantum was evaluated 
by determination of the parasite viability using 
Figure 1. Chemical structures of benzoxazinoids analogs employed in this 
study. Pyr1-5: Pyridoxazinone series; Bex1-5: Benzoxazinone series.
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the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method.19 Initially, 
100 μL of the promastigote suspension prepared in RPMI-
1640 or LIT medium (1 × 106 cells/mL) was added in 
each well of the 96-well microplate. Parasites were then 
treated with two-fold serial dilutions (from 3.12 to 400 
µg/mL) of Bex-derived analogs prepared in 10% dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, USA) and 
the microplates were incubated at 25°C for 48 h. Next, 
20 μL of MTT solution at 5 mg/mL (Sigma-Aldrich, St. 
Louis, USA) was added to the parasite cultures and the 
plates were covered with laminated paper and incubated 
at 37°C for 4 h. Finally, the plates were centrifuged at 
1500 rpm for 15 min at 4°C (Heraeus-Megafuge 11R 
Centrifuge - Thermo Fisher Scientific, Waltham USA) 
and the formazan crystals formed were dissolved by the 
addition of 200 μL 10% DMSO. After further incubation 
for 5 min at room temperature, absorbance at 570 nm 
of samples measured using a microplate reader (Metller 
Toledo, Brazil). Meglumine antimoniate (Glucantime® 
Sanofi-aventis, France) and amphotericin B (Eurofarma, 
Brazil) were included as positive controls, and 10% DMSO 
solution was used as a solvent control. Samples containing 
RPM1-1640 or LIT only were used to control the sterility 
of media and samples containing inoculum and medium, 
but not compounds, were employed as growth controls. 
Cell culture and cytotoxicity assays
Hamster spleen cells were used to test cytotoxicity. The 
cells were kindly provided by Dr. Rosy Iara Maciel de 
Azambuja Ribeiro from of Laboratory of Experimental 
Pathology/UFSJ. The cells were cultivated in saline 
solution (NaCl 0.9%; Synth, Brazil) and maintained at 
37°C in an incubator with an atmosphere containing 5% 
CO2 (Thermo Fisher Scientific, Waltham, USA).
Cytotoxic concentration determinations for 50% 
of the cells in culture (CC50) were evaluated by using 
the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method, following 
protocols outlined in a previous study.19 Briefly, spleen 
cells were exposed for 48h to several concentrations 
of compounds (3, 6.25, 12.5, 25, 50, 100, 200, 400 and 
800 µg/mL) and, afterward, the MTT assay was used 
to quantify the cell viability as was done using the anti-
promastigote assay. Finally, CC50 values were calculated by 
linear regression analysis of absorbance values obtained 
previously.20
Selective index (SI) determination
The selectivity of Bex analogs and antileishmanial agents 
was determined to evaluate the safety of compounds. 
Thus, the selectivity index (SI) was calculated through the 
ratio between the CC50 of compounds against the hamster 
spleen cells and the geometric mean (GM) of IC50 values 
calculated for L. (V.) braziliensis and L. (L.) infantum.21 
In the case where CC50 was higher than the highest 
concentration tested of the compound, to calculate the SI, 
the value used was 400. The larger SI was indicative of a 
safer molecule.
Statistical analysis
All experiments were performed in triplicate and with 
at least three independent experimental repetitions. 
Results are presented as mean ± standard error of these 
repetitions as appropriate. In our statistical analysis, the 
normality of the data was initially evaluated using the 
Shapiro-Wilk test. Subsequent comparisons between the 
groups were carried out using a t-test (two groups) or 
analysis of variance (one-way ANOVA) (multiple groups). 
The Tukey test was used to compare the results of the 
treatments and the Dunnett test to compare the results of 
the treatment and control. A p-value of less than 0.05 was 
considered significant. Statistical analysis was performed 
using GraphPad Prism (version 6) (Graphpad Software 
Inc., San Diego, CA, USA).
Results and Discussion
Bexs are alkaloids, characterized in the 1950s, that are 
commonly found in monocotyledons of the Gramineae 
family, such as rye (Secale cereale), maize (Zea mays) 
and wheat (Triticum aestivum).12 Since then, appreciable 
amounts of Bexs have also been reported in whole 
food products,12 as well as in some dicotyledons of the 
families Acanthaceae (i.e., Acanthus mollis, Aphelandra 
tetragona, A. squarrosa, Blepharis edulis), Ranunculaceae 
(Consolida orientalis), Plantaginaceae (Scoparia dulcis), 
Lamiaceae (Lamium galeobdolon) and Scrophulariaceae.22 
The Bex-derived stand out for their importance as 
allelochemicals, used for plant-plant, plant-insect, or 
plant-microorganisms communication (or interaction), 
and display a wide range of anti-infective, insecticidal and 
antimicrobial activities.12,13,23
In addition to the defensive effect against 
phytopathogens, Bex-derived compounds have also shown 
activity against microorganisms of medical interest.14-17 
Bravo et al15 reported that the Bexs benzoxazolin-2-one 
(BOA), 2-hydroxy-1,4-benzoxazin-3-one (HBOA) and 
2,4-dihydroxy-1,4-benzoxazin-3-one (DIBOA) exhibit 
antibacterial effects against Staphylococcus aureus and 
Streptococcus mutans at concentrations of 500 μg/mL, 
and against Escherichia coli at a concentration of 1,000 
μg/mL according to microdilution broth assays. The 
compound, 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-
3-one (DIMBOA; at a concentration of 2 mg/disk), is 
active against the bacteria Enterococcus faecalis, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Bacillus subtilis, S. 
aureus methicillin-resistant and E. coli extended-spectrum 
β-lactamases produced by disc diffusion.17 In addition, 
the antifungal activity of Bex-derived compounds and 
their metabolites have been recognized against the yeasts 
Candida albicans, Candida glabrata, and Saccharomyces 
cerevisae, and also against molds, Penicillium chrysogenum, 
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Monilia Formosa, Phanerochaete chrysosporium and 
Trichoderma reesei.12,14,17 Wang and Ng16 showed that Bexs 
also have antiviral properties; 6-methoxy-benzoxazolin-
2-one (MBOA) is able to inhibit reverse transcriptase 
from human immunodeficiency virus (HIV). Thus, Bexs 
have proven to be potential sources for the development 
of novel anti-infective agents. However, the antiparasitic 
effect of this class is not understood. Various problems 
associated with the current antileishmanial therapy, 
i.e., high toxicity, serious adverse effects, long course, 
storage, and access difficulties; together with the medical, 
epidemiological and social importance of this zoonosis, 
highlights the need to study the potential antiparasitic of 
Bex-derived compounds against the genus Leishmania.1,7-9 
Here, a set of C-2 substituted Bexs, synthesized using the 
pyridoxazinone and benzoxazinone core as described by 
Lima et al,18 were evaluated for anti-promastigote activity 
against L. (V.) braziliensis and L. (L.) infantum. 
As shown in Table 1, all compounds tested were 
active, with IC50 values falling between 92±6.19 µg/mL 
and 238 ± 6.57 µg/mL against L. (V.) braziliensis, and 
from 89 ± 6.43 µg/mL to 188 ± 3.58 µg/mL against L. (L.) 
infantum. In the concentration of 100 or 200 µg/mL, for 
example, all compounds, including the positive controls, 
were able to significantly reduce the viability of L. (V.) 
braziliensis and L. (L.) infantum promastigotes compared 
to untreated controls (Dunnett, P < 0.05) (Figure 2). The 
compounds Bex2, Bex3, Pyr1, Pyr2 and Pyr4 showed a 
similar to the activities of the drug Glucantime®, which 
is considered the first-line of defense against leishmanial 
disease.9 These compounds, from the concentration of 25 
μg/mL, did not differ statistically in the antileishmanial 
effect when compared to the reference drug. The 
presence of the pyridine ring, although not a significant 
Figure 2. Anti-promastigote activity of benzoxazinoids analogs and positive 
controls at concentrations of 100 µg/mL (A and B) or 200 µg/mL (C and 
D) against Leishmania (Viannia) braziliensis (A and C) and Leishmania 
(Leishmania) infantum (B and D). ANFO: Amphotericin B; MEG: Meglumine 
antimoniate (Glucantime®); OD570nm: Optical density at 570 nm; Pyr1-5: 
Pyridoxazinone series; Bex1-5: Benzoxazinone series. *Difference between 
treated samples and untreated controls, One-Way ANOVA with Dunnett 
pots-test (P < 0.05).
influence in Bex activity has been shown to be an essential 
pharmacophoric moiety in other classes of compounds 
with leishmanicidal potential, such as chalcones,24 
pyrazoles,25 and dyarylimidazoles.26 In addition, the 
Bexs employed in this study had similar effects on the 
promastigotes of L. (V.) braziliensis and L. (L.) infantum, 
suggesting that they may be used in chemotherapy of 
both, CL and VL. 
Similar to Glucantime®, the CC50 values for compounds 
Pyr1 and Pyr2 were higher than the highest concentration 
tested (CC50 >400 µg/mL), suggesting low toxicity (Table 
2). The analogues Pyr 4 (CC50 201.7 ± 2.11 µg/mL) and 
Bex2 (CC50 274.3 ± 1.87 µg/mL) showed both CC50 higher 
that 200 µg/mL, and the compound Bex3 has the lower 
cytotoxic concentration of Bexs tested, with a CC50 of 
105.7 ± 2.26 µg/mL. All of the synthetic compounds 
showed lower toxicity that the drug amphotericin B, 
which has a CC50 of 89.33 ± 2.24 µg/mL (Table 2). SI values 
were calculated to determine the safety and efficiency 
of compounds. As shown in Table 2, SI values ranged 
from1.12 to 4.10 concerning to L. (V.) braziliensis and from 
1.16 to 4.02 against L. (L.) infantum. The antileishmanial 
agent meglumine antimoniate (Glucantime®) had the 
highest SI value with respect to both species studied (4.10 
for L. (V.) braziliensis and 4.02 for L. (L.) infantum). Thus, 
these results showed that the compounds more active 
in anti-promastigote assays has presented low toxicity 
against hamster spleen cells, suggesting that these analogs 
are relatively safe and have a wide therapeutic range. 
Jensen et al27 showed that Bexs obtained through the 
diet are widely absorbed, metabolized and excreted 
mainly by the urinary system. In this crossover study 
Table 1. Effect of benzoxazinoids analogs on the growth of Leishmania 
(Viana) braziliensis and Leishmania (Viana) infantum promastigotes
Compounds
IC50 (µg/mL)
L. braziliensisa L. infantuma
LITb RPMI-1640b LITb RPMI-1640b
Bex1(C) 212±6.04 238±6.57 174±3.39 188±3.58
Bex2 (H) 103±4.36 109±4.44 106±5.61 111±5.69
Bex3(G) 92±6.19 97±6.24 89±6.43 93±6.48
Bex5 (E) 129±4.61 138±4.76 141±5.36 151±5.57
Pyr1(A) 108±5.91 115±6.04 99±5.61 103±5.64
Pyr2 (B) 100±5.18 105±5.23 112±5.34 118±5.45
Pyr3 (I) 141±5.94 152±6.17 149±6.35 160±6.62
Pyr4 (D) 98±5.94 103±5.99 91±6.00 95±6.05
Pyr5 (F) 142±3.67 154±3.85 135±4.13 143±4.25
MEG 97±4.34 98±4.45 97±3.14 102±3.54
ANFO 33.3±3.66 33.4±3.01 41.64±4.27 41.45±0.99
IC50: 50% inhibitory concentration; MEG: Meglumine antimoniate 
(Glucantime®); ANFO: Amphotericin B. 
a IC50 values to L. (V.) braziliensis vs. IC50 values to L. (L.) infantum, P > 0.05 
(Unpaired t test).
b IC50 values in LIT vs. IC50 values in RPMI-1640, P > 0.05 (Unpaired t test).
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with 19 participants, it was shown that plasma and 
urinary Bex levels are proportional to the number of 
ingested compounds. In addition, the pharmacokinetic 
profile showed that they were quickly absorbed, taking 
approximately 3 h to reach the peak plasma levels, 
suggesting the plausibility Bex-derived compounds 
studded here being used as an oral drug.27 Furthermore, the 
secondary therapeutic effects of Bex-derived compounds 
may be advantageous during antileishmanial therapy, 
which include potential anti-inflammatory benefits. The 
Bexs MBOA, HMBOA and HBOA, isolated from roots of 
Coixlachryma-jobi var. ma-yuen, were able to reduce levels 
of histamine released from rat mast cells stimulated with 
concanavalin A and sensitized with immunoglobulin E.28 
In addition, benzoxazinone analogues, synthesized from 
N-(1-(6,8-dibromo-4-oxo-4H-benzo[d][1,3]-oxazin-2-
yl)-2-phenylvinyl)benzamide, showed moderate to high 
anti-inflammatory activity in a carrageenan-induced rat 
paw edema model.29 The anti-inflammatory effect of Bex-
derived compounds is of particular relevance because 
some forms of leishmaniasis, such as mucocutaneous, have 
a crucial inflammatory component pathophysiological 
component.4 However, oral bioavailability, as well as the 
anti-inflammatory activity of the compounds employed in 
this study, have yet to be determined.
Conclusion
Bex analogs were efficiently produced by successive 
nucleophilic substitution reactions followed by reductive 
cyclization. The parasite viability assay showed that 
the analogs designated Bex2, Bex3, Pyr1, Pyr2, and 
Pyr4 have similar levels of antileishmanial activity 
against the promastigotes of L. (V.) braziliensis and L. 
(L.) infantum as the reference drug Glucantime®. In 
addition, these compounds showed low cytotoxicity 
against splenic hamster cells and favorable selectivity 
indices. Thus, we conclude that the analogs in question 
are promising prototypes for the pharmaceutical industry 
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